Breath and blood test could spot lung cancer earlier, reduce false positives

NCT ID NCT07370077

Recruiting now Diagnosis Sponsor: Chen KeZhong Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new way to screen for early lung cancer using a combination of breath analysis, blood tests, and CT scans. Researchers aim to reduce the high rate of false positives from CT scans alone. They will enroll 1,800 participants, including people with lung cancer, benign nodules, and healthy controls, to build a more accurate diagnostic model.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Multi-omics diagnostic test (breath and blood analysis plus CT imaging)
What this could lead to: If successful, this could lead to a more accurate, non-invasive screening method for early lung cancer, reducing unnecessary biopsies and false alarms.
What could go wrong: This is an observational study, not a treatment trial. The new method may not prove more accurate than current CT screening, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

Contacts and locations

Locations

Peking University People's Hospital
RECRUITING

Beijing, Beijing Municipality, 10010, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.